Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Daniel Robert Kuritzkes, M.D.

Co-Author

This page shows the publications co-authored by Daniel Kuritzkes and Rajesh Gandhi.
Connection Strength

0.890
  1. Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. J Infect Dis. 2017 07 15; 216(2):254-262.
    View in: PubMed
    Score: 0.184
  2. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016 Jan 28; 30(3):343-53.
    View in: PubMed
    Score: 0.167
  3. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis. 2007 Dec 01; 196 Suppl 3:S449-56.
    View in: PubMed
    Score: 0.095
  4. Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366. AIDS Res Hum Retroviruses. 2020 04; 36(4):268-282.
    View in: PubMed
    Score: 0.056
  5. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268.
    View in: PubMed
    Score: 0.052
  6. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.
    View in: PubMed
    Score: 0.050
  7. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085.
    View in: PubMed
    Score: 0.050
  8. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. J Virol. 2018 06 15; 92(12).
    View in: PubMed
    Score: 0.049
  9. Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathog Immun. 2017; 2(3):431-445.
    View in: PubMed
    Score: 0.047
  10. Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. . 2016 07 01; 72(3):310-3.
    View in: PubMed
    Score: 0.043
  11. Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa. PLoS One. 2013; 8(12).
    View in: PubMed
    Score: 0.036
  12. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS One. 2012; 7(9):e44793.
    View in: PubMed
    Score: 0.033
  13. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.